Acumen Pharmaceuticals Inc. (ABOS) used Citigroup's Biopharma Back to School Summit on September 10, 2026, to present updated clinical and pipeline data on its lead Alzheimer's asset and a next-generation brain-delivery platform.
CEO Dan described the company's scientific thesis as centered on neutralizing amyloid-beta oligomers — small soluble protein aggregates he called "potently toxic" — rather than fibrillar amyloid alone. He said Acumen believes this approach could yield "greater efficacy and safety" compared with existing amyloid-targeting therapies such as Eisai-Biogen's lecanemab (Leqembi) and Eli Lilly's donanemab (Kisunla), which have together reached annual sales run rates exceeding $1 billion.
At the phase 2 ALTITUDE-AD trial, Acumen enrolled 542 patients across three arms — 35 mg/kg and 50 mg/kg intravenous doses of sabirnetug plus a placebo arm — over a 10-month enrollment period. A higher 60 mg/kg dose tested in phase 1 was dropped before phase 2. The study, an 18-month double-blind trial followed by a 12-month open-label extension, uses the iADRS composite scale as its primary endpoint, alongside CDR-Sum of Boxes, amyloid and tau PET imaging, MRI safety scans and plasma biomarkers. Pre-screening relied on plasma p-tau217 to confirm amyloid positivity and reduce screen-fail rates. More than 95% of eligible patients enrolled in the open-label extension.
Phase 1 safety data showed an overall ARIA rate of roughly 10% — five events among 50 subjects — with four classified as non-symptomatic and one mildly symptomatic. Three of those five events occurred at the 60 mg/kg dose that was not advanced into phase 2. Management said its efficacy target for sabirnetug is approximately a 30% slowing in cognitive decline, within the 27%-32% range seen with approved amyloid therapies.
Top-line results from the ALTITUDE-AD trial are expected in late Q4 2026, according to management, which stressed the reading is a quarter event rather than a calendar-year-end event. Acumen aims to disclose the data in what CEO Dan called a "fulsome" and actionable format rather than previewing results at future conferences.
On the pipeline front, Acumen outlined its Enhanced Brain Delivery (EBD) program developed in partnership with Japan's JCR Pharma. The bispecific construct uses transferrin-directed transport to improve brain penetration of antibody therapeutics. In non-human primate studies, the platform achieved 20-fold to 40-fold higher cortical exposure versus unmodified native antibodies, a company executive noted, compared with the commonly cited baseline that only about 0.1% of a circulating plasma antibody dose reaches the brain. Two pre-clinical candidates carry the platform: ACU301, which fuses sabirnetug to the carrier technology, and ACU401, which links the same carrier to ACU234, an analog from Acumen's library.
Acumen anticipates selecting a lead EBD candidate and filing an investigational new drug application around mid-2027. The initial target population for the enhanced version is expected to be pre-clinical Alzheimer's patients — amyloid-positive, cognitively normal individuals projected to progress within three to five years.
Looking at the broader market, Acumen projected that approved amyloid-targeting drugs will surpass $2 billion in sales by 2028 and reach $3 billion to $4 billion by 2030.
